TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Jul 27, 2022 4:53pm
100 Views
Post# 34855045
RE:LSDs and Other Speculations
RE:LSDs and Other Speculations "Finally, pof made the following comment, "BTI is positioned to be a potential strategic monster in the Lysosomal Storage Disorder space."
I'm not sure I agree with that. Bioasis sold four LSDs to Chiesi for $3 million and $138 million in milestones, which is only about $45 million each. Bioasis low royalty rates (1%, so far) have not inspired confidence. These are not monster-making numbers. I expect Bioasis to gain recognition for its contribution but Bioasis will not gain much financially from it all. Like I say, I hope xB3-008 remains wholly-owned by Bioasis but I'm sceptical of that."
BTI only licensed four LSD applications to Chiesi.
BTI kept 100% of xB3-008 for Hunter Syndrome and can take it to human testing next year. It can piggy-back off Denali's data too. Hunter is one of the larger LSD opportunities.
Gaucher's is the largest LSD opportunity and BTI kept it internally though it has a partner in Oxyrane. The enzyme also has application for Parkinson's and Lewy Body Dementia. Oxyrane's technology is for mannose 6-phosphate dependent enzymes.
Neurodegeneration is also a component of LSDs. including Fabry. BTI kept this opportunity with xB3-004.
BTI may have given Chiesi four xB3 opportunities in the LSD space and married the potential emerging standard of care for Fabry to xB3, but BTI kept many potential key opportunities in the LSD space for itself; potentially setting the stage for an additional agreement with Chiesi as Chiesi develops its strategic position in the space through FDA and European approval of Fabry, etc. BTI will also be able to advance its LSD pipeline ahead of the next LSD deal thereby adding value.